# LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

> **NCT01015118** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1366 (actual)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Placebo
- **DRUG:** Paclitaxel
- **DRUG:** BIBF 1120
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01015118
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-17
- **Primary completion:** 2013-04-01
- **Final completion:** 2016-09-15
- **Target enrollment:** 1366 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015118, "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01015118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*